INTRODUCTION
The name "enterocoque" was first used by Thiercelin in a paper from France published in 1899 (206) ; the name was proposed to emphasize the intestinal origin of this new gram-positive diplococcus. In the same year, MacCallum and Hastings reported a case of endocarditis caused by an organism they called Micrococcus zymogenes; later papers suggest that this organism was actually a hemolytic enterococcus (191) . The name Streptococcus faecalis (faecalis, relating to feces) was first coined in 1906 by Andrewes and Horder, who isolated this organism from a patient with endocarditis and considered that this streptococcus was "so characteristic of the human intestine that the term 'streptococcus faecalis' may justly be applied to it" (2) .
Over the next decade or so, various authors studied and wrote about isolates that they also referred to as S. faecalis, but in 1919 Orla-Jensen used different terminology when he described strains of S. gh'cerinaceus and S. faecium (163) . For a number of years, these names were largely ignored and the organisms were considered to be the same as S. faecalis (191) . Differences of opinion regarding nomenclature existed not only for S. fJecalis, but also for the common name, enterococcus. In an excellent review in 1937, Sherman (191) emphasized that the term enterococcus had been used to mean different things ranging from the broad definition of any fecal streptococcus to a restricted definition of organisms that appeared to be identical to S. faecalis. Sherman proposed a classification scheme which separated strepto-cocci into four divisions: pyogenic, viridans, lactic, and enterococcus. The latter term was used for organisms that (for the most part) grew at 10 and 450C, in 6.5% NaCi, and at pH 9.6 and which survived 60'C for 30 min; the ability to split esculin was also noted (191) . Many of these characteristics became widely used to distinguish between enterococci and nonenterococcal streptococci, such as S. hovis, and some are still used today to help identify enterococci. Sherman's classification scheme also correlated with the serological scheme originated by Lancefield in the early 1930s. In that system, the enterococci reacted with group D antisera, while the pyogenic streptococci reacted with group A, B, C, E, F, or G and the viridans streptococci were nongroupable; S. boiis, classified by Sherman as a viridans streptococcus, was later shown to react with group D antiserum. Within the enterococci, Sherman described what were at that time the generally recognized enterococcal species, S. faecalis, S. zviogenes, S. liquefjaiens, and S.
duirans. However, because of the similarities of the first three of these, he suggested that the more appropriate terminology would be as follows: S. Jaeccalis (hemolysis negative, proteolysis negative), S. filwcalis var. liqueftwciens (hemolysis negative, proteolysis positive), S. faecalis var. hemolvticus (hemolysis positive, proteolysis negative), S. faecalis var. zymogenes (hemolysis positive, proteolysis positive), and S. durans. More recent work has shown that hemolysis is plasmid mediated and can be transferred to nonhemolytic strains, confirming the inappropriateness of using this characteristic to distinguish species (102) .
Although the species that Orla-Jensen in 1919 had named S. ghcerinaceus and S. faecium were considered by Sherman to be the same as S. Jtuecalis (191) , a number of studies in the 1940s and 1950s showed that organisms referred to as S. fJuecilm had biochemical characteristics that distinguished them from S. ftecalis. Such differences included inhibition by potassium tellurite, fermentation reactions, and failure to reduce tetrazolium to formazan (8, 49, 93) . Although S. faecium was not officially recognized as a separate species in the 1957 Bergev's Manual of Determinative Bacteriology (19) , the species status of these organisms was nonetheless widely accepted and was incorporated into official nomenclature by the mid-1960s (8, 19, 23, 49, 117) . During this period, S. durans was sometimes listed as a separate species and sometimes referred to as a variant of S.
faeciulm (19, 23, 49) .
In addition to the familiar organisms mentioned above, a number of other enterococci have been isolated from human, animal, food, and plant sources. Motile enterococci were noted as early as 1935, and some that resembled S. fieciumn became known as S. faeciiim subsp. mnobilis (23, 88, 101, 117, 169) . Some motile enterococci were noted in the 1950s to produce a yellow pigment, and in 1968 the name S. fJaecium var. casseliflav'us (for yellow colored) was suggested (88, 147 ). An enterococcus isolated from Gouda cheese was referred to in 1955 as "malodoratus'' because of its bad smell (43) . Some strains of enterococci were found to react not only with Lancefield's group D antiserum but often with group Q as well. Because these organisms resembled enterococci from chickens, the name "Streptococcus aviumn"' was proposed in 1967 (160) ; this name was recognized in the 1974 Bergev's Manual (50) .
In the past decade, the use of nucleic acid relatedness has clarified and expanded the classification scheme for enterococci. Farrow et al. in 1983 presented biochemical and DNA hybridization data that indicated that S. faecalis, S.fJaeciumn S. casseliflai'us, S. av'iumn, S. durans, and S. fJecalis var. inalodoratus were all distinct; that ''S. fuecium var. niobilis' was the same as S. casselflal'us; that S. ftecalis and its former subspecies liquefricienis and Zv'nogenes were indeed one species; and that some group D enterococci from chickens, designated S. gallinarumn, were distinct from S. alviuln (20, 70) . Schleifer and Kilpper-Balz in 1984 used DNA-DNA and DNA-rRNA hybridization to show that S. fuecalis and S. faeciuin were so distantly related to streptococci. including S. boi'is, that they should be transferred to another genus; it was similarly proposed that the group N lactic streptococci should be transferred to a new genus, Lactococcus (187) . The proposal to transfer enterococci to a new genus named Enterococcuts had been previously suggested, and it was this genus name that was proposed by Schleifer and Kilpper-Balz (187) . Shortly thereafter, Collins, Jones, and Farrow, working with Kilpper-Bdlz and Schleifer, used similar methodology to show that strains called S.
ai'iin, S. casseliflai'us, S. durans, S. Jufecalis subsp. ,nalodoratus, and S. gallinaruin were sufficiently closely related to other members of the genus Enterococcus to be transferred to this genus but sufficiently distinct to be considered separate species (43) . The names proposed were Enterococ-(us aviumn, E. casseliflavuts, E. duirans, E. inalodoratuts, and E. gallinarutin (43) . These two important papers were published during the preparation of the 1984 Bergey's Manual (186) , and the genus Enterococcuts was not incorporated into the official nomenclature; however, this work was cited in Bergey's Manual and considered to support fully the creation of a new genus to encompass the enterococcal group of organisms (186) . Nucleic acid studies have also been used to define other species within the proposed genus, including Enterococcus liirae (hirae, meaning of the intestine or gut), which includes some organisms previously classified as S. diirans, and E. tnundtii, which includes some atypical nonmotile pigmented strains (42, 69, 110) . Three other new species, E. raffijinosus, E. solitaius, and E. pseudoali'im, have also been proposed (66) , and some enterococci still have not been identified to species. The (65, 187, 191) .
In clinical laboratories, enterococci have been presumptively identified for years by their appearance on smear and VOL. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from culture plus the demonstration of their ability to hydrolyze esculin in the presence of bile and to grow in the presence of 6.5% NaCl (62, 63 (86) . Although the above screening tests appeared to be sufficient in the past to identify enterococci presumptively, it is now recognized that other less commonly encountered gram-positive cocci can also give a positive reaction in some of these tests (65) (66) (67) . For example, some cultures of Lactococcus, Aerococcus, Pediococcus, and Leuconostoc spp. are bile-esculin positive or can grow in 6.5% salt or both. Strains of Pediococcus and Leuconostoc spp. can be group D positive, and some lactococci and aerococci are PYR positive; lactococci and aerococci, however, should not react with group D antisera. Leuconostocs show no zone of inhibition around a 30-,ug vancomycin disk, are PYR negative, and produce gas from glucose, whereas enterococci are PYR positive and do not produce gas from glucose; also, although vancomycin resistance has now been reported, the vast majority show a zone of inhibition around vancomycin disks. A battery of tests, including gas from glucose, vancomycin susceptibility testing, group D antiserum reaction, bile-esculin, PYR, and growth in 6.5% NaCl and at 45 and 10°C, may be necessary (Table 1) . For further details, the reader is referred to recent papers by Facklam and Collins (66) and Facklam et al. (67) .
Species Identification
In many instances, it may not be necessary to identify enterococci to species. For example, with urinary tract and wound isolates, presumptive identification to the genus level together with determination of susceptibility to selected antimicrobial agents such as penicillin, ampicillin, and vancomycin is generally sufficient. However, with certain infections, especially endocarditis, differentiation between E. faecalis and E. faecium (the two most commonly encountered enterococcal species) can be helpful because of the naturally occurring differences in the susceptibility of these species (see below). Currently, it is not known whether the less commonly encountered enterococcal species differ importantly in their susceptibility, but now that criteria are available for identifying them, perhaps more laboratories will look for these species and accurate numbers regarding their incidence and susceptibility can be determined (66) .
Another reason for species identification of enterococci is that it may be useful for epidemiologic surveillance within hospitals. Although enterococci were not previously thought of as nosocomially spread pathogens, recent studies have confirmed this route of transmission (126, 232) ; an increase in the number of isolates of E. faiecium or especially an increase in the rarely encountered species would be an epidemiologic clue to the presence of an outbreak (46, 216) .
Between 80 and 90% of clinical enterococcal isolates in recent studies have been E. faecalis (114, 129, 172, 193) , with E. faecium a distant second; therefore, this is the differentiation that should be most commonly made. In addition to the low degree of DNA relatedness between these species, a number of biochemical differences facilitate their differentiation. E. faecalis, for example, has the LysAla2-3 type of peptidoglycan and has demethylmenaquinones, whereas E. faecium contains the LyS-D-Asp type of peptidoglycan and has neither menaquinones nor ubiquinones (187) . Differences that can be readily detected in clinical laboratories include the ability of most E. faecalis, but generally not E. faecium, to grow on medium containing 0.04% tellurite and to reduce tetrazolium to formazan; however, many of the other enterococcal species resemble E. faecium in these tests, and E. mundtii are often like E. faecalis. Other differences are that most E. faecalis but not E. faecium produce acid from D-tagatose, sorbitol, and glycerol, whereas most E. faecium but not E. Ja'ecalis produce acid from melibiose and L-arabinose (43, 65, 66, 187) . Several biochemical reactions can be suggestive of the other enterococcal species (42, 43, 66, 69) . E. casseliflavuis, for example, is motile and produces yellow pigment; E. mundtii produces yellow pigment and is not motile; E. gallinarum is motile but does not produce yellow pigment; and the other enterococcal species neither are motile nor produce yellow pigment (42, 43, 187) . The papers describing these new species used a combination of conventional tests and dehydrated miniaturized tests (42, 43, 69, 187, 229) , the results of which usually, but not always, agree (78) .
Clinical Phage and bacteriocin typing have been applied to enterococci at various times over the past two decades (33, 109, 115, 166, 167, 212) . A recent publication reported a typing scheme, using both phage and enterococcines, with over 900 enterococci from two hospitals (114) . A large percentage (79%) could be typed into one of 25 phage types, although 61% belonged to a single phage type. Seventy-nine percent could also be placed into one of six enterococcine groups which consisted of 85 enterococcinotypes; half belonged to one group. When phage typing was combined with enterococcine typing, 87% of strains could be typed. Among these strains, 187 types were obtained by combining species, phage type, and enterococcinotype (114) .
At the current time, it is not known whether the standard for epidemiologic typing of enterococci should be plasmid typing, phage with or without bacteriocin typing, or some other technique, such as chromosomal digestion patterns, which may be applied to enterococci in the future. It will be of interest to compare these various techniques in epidemiologic studies of the same strains.
HABITAT Enterococci are found in the feces of most healthy adults; in several recent studies from Japan, Federal Republic of Germany, and Scandinavia, enterococci were found in 97% of 71 individuals studied (14, 15, 55, 59, 134, 159, 190) . When enterococci from feces have been identified to species, many studies report that E. faecalis is more common and is found in higher numbers than E. faeciulm (14, 59, 114, 159, 190) . Studies from some locations, however, have reported that E. faeciunm is found more often than E. faecalis (134) . Noble examined feces from 6-to 7-day-old infants and from inpatient and outpatient adults (159 (159) . Benno et al. compared the fecal microflora of nine rural Japanese with eight urban Canadians and found that 100% of both groups had E. faecalis; these organisms were present at about 6.5 log10 CFU/g (14) . E. fueciuam was found in two individuals in each location; E. dluraJns was found in one Japanese and in no Canadian individuals (14) . Two other recent studies from the Federal Republic of Germany found E. faecalis in 21 (59, 190) .
Enterococci are less commonly found at other sites such as in vaginal (17% in one study [12] ) and oral (116, 196) specimens, and results are sometimes quite variable. In a study of the dental plaque of healthy students, academic staff, healthy toothache patients, and hemodialysis patients and staff, enterococci were found in approximately the same percentages in the various groups (10% overall), although patients and staff in one particular hospital had carriage rates of 60%; almost all isolates were E. faecalis (196) . In another study, higher rates of enterococcal carriage were found among long-term hemodialysis patients and cardiac patients than among their staff and acute dental patients; in this study, E. faeciun outnumbered E. fJecalis isolates (31) .
CLINICAL INFECTIONS Historical Perspective
Enterococci have been recognized as being potentially pathogenic for humans since the turn of the century. What VO0L. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from was probably the earliest review of the literature on human diseases associated with enterococci appeared in 1912, and several reviews were published in the 1920s (reviewed by Sherman [191] ). Even though some of these early isolates were probably not enterococci as they are now defined, many of the clinical syndromes described years ago continue to be seen today. In Thiercelin's original description of entdrocoque in 1899, he found these organisms in patients with enteritis, appendicitis, and meningitis (206) , none of which are commonly associated with enterococci today. Also in 1899, as was mentioned earlier, an organism isolated from a patient with endocarditis was called "Micrococcus zymogenes," but was later thought to be S. faecalis var. zymogenes (191) . The organism Andrewes and Horder called Streptococcus faecalis in 1906 was also isolated from a patient with endocarditis (2); Hicks in 1912 (191) and a number of subsequent workers confirmed the association of enterococci with endocarditis (61, 191) . The role of enterococci in urinary tract infections (UTIs) was first reported by Andrewes and Horder in 1906 and was extended in subsequent decades by other investigators (2, 61, 191) . Early authors also noted an association of enterococci with puerperal sepsis and with purulent abdominal infections following damage to the intestinal tract (61, 191) . In World War I, a number of authors reported enterococcal wound infections, although it was not established whether this organism was colonizing or truly causing infection (61) . Other enterococcal infections that were reported in the early years include osteomyelitis, cholecystitis, and dental infection (61) . Some of these reports may not have been describing organisms that were truly enterococci or the cultures may have contained other organisms that were missed or were disregarded. One of the more obvious examples is the role that was postulated for enterococci in enteritis or food poisoning or both. This apparent misconception probably arose because of the common occurrence of enterococci in the intestinal tract and thus in fecally contaminated foods. On the other hand, a recent article implicated a strain of E. hirae, which probably came from the stool of a human with diarrhea, as a cause of diarrhea in suckling rats (60) .
Endocarditis
Enterococci cause an estimated 5 to 15% of bacterial endocarditis. As with other enterococcal infections, most isolates are E. faecalis (81, 141, 185, 226) ; however, other species can also cause this disease. Among isolates sent to the Centers for Disease Control, endocarditis was the diagnosis given for patients from whom E. avium, E. casseliflavus, E. durans, E. gallinarum, and E. raffinosus, as well as E. faecalis and E. faecium, were isolated (66). The average age of patients in one recent study of enterococcal endocarditis was 65 years; this is somewhat older than the age in studies of several decades ago, perhaps reflecting a generally aging population (111, 131, 226) . Enterococcal endocarditis occasionally occurs in children and rarely in infants (128, 203) . Males predominate and, at least in the earlier studies, have been older than the women with this disease. Mandell et al., reporting patients from 1945 to 1968, found an average age of 59 years in the 22 men and 37 years in the 16 women they studied (131) . During this time period, Koenig and Kaye also reported a mean age of 56 years in men and 35 years in women (111) . The disease may present as an acute or subacute illness. Common risk factors for enterococcal endocarditis included genitourinary and biliary portals (111, 131, 226) . In Mandell's study, 50% of the men had preceding genitourinary instrumentation or UTI; 38% of the women had a preceding genitourinary source including abortion or instrumentation (131) . Underlying heart disease is often present but is not a prerequisite for the development of this disease (111, 129, 131, 172, 174, 226 (172) . Unlike staphylococcal endocarditis in addicts, the valves involved by enterococci are usually aortic and mitral. These patients usually have no history of antecedent valvular disease and often present with congestive heart failure (172).
Enterococcal Bacteremia Enterococcal bacteremia is much more common than enterococcal endocarditis. In two studies, which reviewed all blood cultures positive for enterococci, 2 of 114 (1.7%) and 2 of 79 (2.5%) patients were thought to have endocarditis (80, 221) . Higher percentages have also been reported, but the cases were selected differently. For example, Shlaes noted in his review that there were 13 cases with pure cultures of enterococci from the blood in the last 4 years of the study and 6 patients (32%) with endocarditis; this study included only patients with two or more positive blood cultures and did not include those with polymicrobial bacteremia, a common accompaniment to enterococcal bacteremia (193) . Malone et al. studied 55 patients with enterococcemia and found endocarditis in 5 patients (9%); however, this study included only patients with two or more positive blood cultures or one positive blood culture plus isolation of the organism from normally sterile sites or from surgical or autopsy specimens (130) . Using a similar definition, Maki and Agger found 13 cases of endocarditis among 153 cases of enterococcemia (8%) (129) . Twelve of their cases of endocarditis occurred among the 33 patients with communityacquired enterococcal bacteremias (36%) and only one occurred among the 120 patients with nosocomial bacteremia (0.8%). This review also emphasized that there had been a steady increase in the number of patients with enterococcemia since 1975, even though there was little change in the number of admissions; this increase was due entirely to an increase in nosocomial bacteremias (129) .
The source of enterococcal bacteremia without endocarditis is often the urinary tract: 23% of patients in the study by Shlaes et al. (193) , 19% in the study by Garrison et al. (80) , and 24% in the study by Malone et al. (130) . In Maki and Agger's report, 77% had either a urinary or an intravascular catheter (129) . Intraabdominal, biliary, pelvic, and wound sources are also common (80, 122, 129, 130, 193) . Other sources include burn wounds, peripartum mothers and infants, bone, and intravascular catheters (45, 80, 129, 130, 193) . Polymicrobial bacteremia, either simultaneous or in separate but temporally related blood cultures, is very common, ranging from 24% in a study requiring two or more positive enterococcal blood cultures for inclusion to 45% in a study which included all positive enterococcal blood cultures (80, 129, 193) .
Mortality of enterococcal bacteremia has generally been high, most probably because of the underlying complicating factors. In the study by Shlaes et al., it was 34% and was significantly associated with burns, hospital-acquired infections, and serious underlying illness but not with the sex of the patient or with the presence of polymicrobial bacteremia (193) . Nine of 14 diabetics, 6 of 10 patients with malignancy or granulocytopenia, 7 of 8 with renal failure, and 3 of 5 alcoholics died (193) . In the study by Malone et (199) . In persons who have been instrumented, received antibiotics, have structural abnormalities, and/or have recurrent UTIs, the rate of urinary colonization and infection by enterococci rises (92, 215) . A dramatic example illustrating some of these features was the study by Gross (24) . Most of these infants had not been instrumented and were of normal to near-normal birth weight; one infant was 25 days old and was admitted from home (24) . Siegel (194) . Group B streptococci were the most common organisms found with a rate of 3.2; the rate of "group D streptococci" was 1.2, and for Escherichia coli, it was 0.9. Among the group D streptococci, the incidence rates for enterococci ranged from 0.6 to 2.0 over the 4-year period as compared with the rates for Escherichia coli, which ranged from 0.4 to 1.4. Early-onset septicemia was the usual presentation for neonatal group D streptococcal disease (194) .
An outbreak of E. faecium occurred in infants in the Neonatal Intensive Care Unit at the Medical College of Virginia Hospitals in 1982 (46) . The children had many of the features commonly associated with nosocomial enterococcal bacteremia: all had severe underlying disease, nasogastric tubes, and multiple intravascular devices, were premature, and had received total parenteral nutrition. Cultures of blood and cerebrospinal fluid (CSF) were positive in four patients, blood only was positive in two patients, and CSF only was positive in one patient. The lack of recovery of E. faecium from neonates over the previous year plus certain biochemical characteristics of these isolates led these authors to conclude that these E. faecium represented the same strain and that the outbreak was most likely due to spread by hospital personnel (46 (126) . All E. faecalis-infected infants were premature and of low birth weight and often had bowel resection and a longstanding central line in place (126) . Nosocomial transmission has also been documented among a large number of infants at Boston Children's Hospital, Boston, Mass.; beta-lactamase production, an unusual feature, proved to be an important epidemiologic marker (E. Rhinehart, C. Wennersten, E. Gross 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from children and adults. Most cases seem to be related to an underlying disorder. In a 1961 review, 12 of 294 cases of meningitis appeared to be caused by enterococci; many of these patients were said to have had a long-term primary illness, invasive procedures of the central nervous system, or prior antibiotic therapy or all three (56) .
In case reports reviewed by Bayer et al., enterococcal meningitis was reported in one patient with meningeal leukemia who was receiving intrathecal chemotherapy, in two children with spina bifida, in one with meningomyelocoele, in one patient following a basilar skull fracture, and in one patient (who had recurrent enterococcal meningitis) with a communication between a mediastinal cyst and the spinal subarachnoid space (11) . Of the three patients in this paper who were studied by the authors, one had meningomyelocoele and one was recovering from intracranial surgery for repair of an arteriovenous malformation; the third patient had no known central nervous system abnormality but had obstruction of the urinary tract due to prostatic cancer and an enterococcal UTI. All three of these patients had CSF leukocyte counts of <50/mm3, and most of the patients reviewed had CSF leukocyte counts of <200/mm3 (11) .
Ryan et al. reported a patient with enterococcal meningitis that was atypical for two reasons (178) . First, the patient's only compromising condition was that he was receiving prednisone (30 mg) every other day for chronic obstructive lung disease; second, his CSF leukocyte count was 4,000/ mm3 on admission, decreased to 311/mm3 on chloramphenicol, and then increased to 7,600/mm3 (with a CSF glucose of 27 and a repeat positive CSF culture) when he relapsed, still on chloramphenicol (178) . Enterococci have also been reported as a cause of central nervous system shunt infections, particularly those that terminate in the peritoneum (2 of 19 ventriculoperitoneal infections) or ureters (2 of 14 ventriculoureteral infections and 1 of 9 lumboureteral infections) (188).
Intraabdominal and Pelvic Infections Although enterococci are part of the normal intestinal flora of most persons and are found in about 17% of routine vaginal cultures, the need to empirically or prophylactically treat for the enterococcus in intraabdominal and pelvic infections remains somewhat controversial (12, 52) . The data from animal experiments indicate that enterococci do not cause sepsis when injected intraperitoneally alone but can act synergistically with other organisms or substances to cause abscess formation (162, 214, 220, 223a) . Moreover, antibiotic regimens that have little or no in vitro activity against enterococci, but which have activity against anaerobes and Escherichia coli, have been successfully used in most patients with intraabdominal and pelvic infections (10, 32, 71, 94, 168, 201, 225) . The discrepancy between in vitro and clinical results is also seen in the rat model of enterococcal intraabdominal abscess in which combinations of clindamycin or metronidazole plus gentamicin have some benefit and are bacteriostatic in vivo against enterococci (223a).
Despite the difficulty in establishing pure enterococcal infections, it is clear that enterococci can cause and contribute to abdominal and pelvic abscess and sepsis. For example, enterococci have been reported as a cause of spontaneous peritonitis in both cirrhotics and nephrotics and can cause peritonitis in patients on chronic ambulatory peritoneal dialysis (48, 87, 123, 219) ; some of these isolates were reported to be pure cultures of enterococci, although it is not always stated that anaerobic cultures were performed. Enterococci have also caused acute salpingitis, peripartum maternal infection (such as endometritis) with bacteremia, and abscess formation following Cesarean section (83, 122, 161, 193) . In one study of 144 bacteremias in obstetrical and gynecological patients, 18 (13%) were due to enterococci, placing it second in frequency behind Escherichia coli; although the sources were not identified, it is clear that the majority were not from a urinary source (122) . Enterococcal abscesses and bacteremia also occur with intraabdominal and biliary infections (53, 80, 129, 193, 231 (137) . This infection occurred in 38 (6.6%) of 572 patients who had a UTI; of note, 28 of these 38 had urinary catheters, which is also considered a compounding factor in the development of enterococcal UTIs. The sources of seven enterococcal bacteremias were wound, peritoneal fluid, the bile duct, the urinary tract, and unknown (137) .
Pneumonia, an infection rarely caused by enterococci, and other infections have also been reported in patients treated with moxalactam (16, 137, 207, 230) . Enterococcal pneumonia has also been seen following the use of polymyxin aerosol for prevention of Pseudomonas aeruginosa pneumonia; in addition to patients with pneumonia, 11 of 292 patients were colonized in the respiratory tract by enterococci (74) . Enterococci were found in the urine of 8 of 45 patients (17.8%) treated with aztreonam; 7 of these had a Foley catheter and the eighth had a nephrostomy tube. Three of these patients were thought to be colonized and five were thought to be infected, including one with bacteremia (37).
Zervos et al. reported two patients with enterococcal infection following intravenous ciprofloxacin therapy. Both had long, complicated illnesses typical of enterococcal superinfection. One had suffered a perforated cecum, and E. faecalis was present in the initial cultures. Following courses of piperacillin, imipenem, ceftazidime, tobramycin, amphotericin, and, finally, ciprofloxacin plus tobramycin for recurrent P. aeruginosa infection, an abdominal abscess and bacteremia due to E. faecalis occurred. The other patient had a necrotic left colon resected and was treated with piperacillin, tobramycin, imipenem, and then ciprofloxacin plus tobramycin for P. aeruginosa. After about 3 weeks of these various therapies, E. faecalis was found in abdominal abscesses along with P. aeruginosa, Candida spp., and Proteus vulgaris. After 5 more days of ciprofloxacin and tobramycin, the patient became bacteremic with E. faecalis (231) . These patients likely represent persistence of E. faecalis following fecal spillage and illustrate the important role enterococci can play in this type of patient, even when anti-enterococcal therapy has been used.
Nosocomial enterococcal infection has also been reported in transplant patients. A recent paper from England reported an unusually high rate of enterococcal bacteremia in liver transplant patients. Although prior antimicrobial therapy is not specifically mentioned, it is highly likely that most received some type of antibiotic (216) . In this report, 21 of 104 episodes of bacteremia were due to E. faecalis and 23 of 104 were due to E. faecium; recurrent bacteremia was seen in 4 patients with each species. The most common source was the biliary tract; enterococcal colonization of T-tubes, which were usually left in for 2 to 3 months, was said to be common (216 (139) .
In vitro testing of E. faecalis shows that MICs of penicillin (average, 2 to 8 pug/ml) are at least 10 to 100 times greater than those for most streptococci (158, 165, 209, 210) . E. faecium is even more resistant and typical MICs of penicillin are often 16 to 32 jig/ml or higher (138, 139) . Occasional papers have listed strains of enterococci with penicillin MICs of 25 to >100 jig/ml (13, 46, 82, 209, 224 ) (see also below). MICs of ampicillin and the ureidopenicillins for E. faecalis are usually 1 to 4 pug/ml, about 1 dilution lower than for penicillin. Resistance to the semisynthetic penicillinaseresistant penicillins is more pronounced, with MICs in the range of 8 to 50 pLg/ml for nafcillin and usually -50 jig/ml for methicillin (72, 153, 158, 209, 210) . In addition, Glew and Moellering reported decreased susceptibility of enterococci to nafcillin, oxacillin, and methicillin when tested in 50% serum-50% broth versus broth alone and showed that the presence of 50% serum completely eliminated synergism with oxacillin and eliminated 80% of the synergistic effects seen with nafcillin (84) . MICs of carbenicillin and ticarcillin are often 64 ,ug/ml, comparable to those for P. aeruginosa (72, 158) . As with the penicillins, imipenem is more active against E. faecalis than against E. faecium but is not bactericidal (7, 153, 158) . Aztreonam lacks activity against gram-positive organisms.
In addition to the high MICs, enterococci are typically "tolerant" to all beta-lactams; that is, they are not killed by concentrations manyfold higher than the MIC. Although in some reports the MBCs as determined by the broth microdilution method have been low, the MBCs of penicillin, VOL. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from ampicillin, and other penicillins in broth macrodilution systems are typically >100 jig/ml (7, 113, 139) .
A notable weakness of cephalosporins is that none of these agents routinely inhibits enterococci sufficiently to warrant its clinical use. MICs of cephalothin range from 6.3 to >100 pug/ml; but MICs of cefoxitin and moxalactam are higher (72, 113, 158, 209, 218) . Although the in vitro activity of cephalosporins against enterococci is poor when tested by conventional methods, MICs may be lower in the presence of serum and lysed blood (179) . The significance of this observation is not known since enterococcal superinfections occur in patients (and thus in the presence of serum and blood) receiving cephalosporins or cephalosporins plus aminoglycosides (218) .
Clindamycin. Another characteristic feature of enterococci is their resistance to clindamycin and lincomycin (107, 209 Aminoglycosides. Low-level resistance to aminoglycosides is also an inherent property of enterococci. The actual level of resistance varies among the different aminoglycosides. For E. faecalis, the average MIC of streptomycin or kanamycin is around 250 pug/ml, whereas gentamicin and tobramycin MICs are 8 to 64 p.g/ml (135, 138, 210) . HLR also occurs and is discussed below. Low-level aminoglycoside resistance among E. faecalis strains appears to be due to low uptake of these agents. If one looks at the uptake of radiolabeled aminoglycosides, it can be shown that, when enterococci are grown in the presence of cell wall synthesis inhibitors, such as penicillin or vancomycin, uptake of the aminoglycoside is markedly enhanced (142, 236) . In turn, the presence of an aminoglycoside results in enhanced killing, the well-known synergistic effect of cell wall synthesis inhibitors plus aminoglycosides.
For all E. faecium strains reported, MICs of tobramycin, kanamycin, netilmicin, and sisomicin are higher than those for E. faecalis; moreover, combinations of penicillin plus these aminoglycosides fail to show synergism against E. faecium (138, 145, 223) . Strains of this species that have been examined produce low levels of an aminoglycoside 6'-acetyltransferase (6'-AAC) that can barely be detected unless strains are pregrown on one of its substrate aminoglycosides (38, 145) . This enzyme and low-level resistance could not be transferred or cured by novobiocin, suggesting that the enzyme may be encoded in the chromosome (145 (41) . These plasmids respond to clumping-inducing agents, or "pheromones," from recipient cells by producing aggregation substance; this substance causes the characteristic and grossly visible clumping between donors and recipients (40) . The third type of conjugative system in enterococci involves conjugative transposons (40) . Transfer (1, 6, 22, 209) . When studied, this resistance has been mediated by chloramphenicol acetyltransferase (22 faecalis (22, 26) . tetO has also been found in enterococci; it was originally found in Campylobacter spp. and shows about 75% homology with tetM (118, 197) . These various genes confer resistance by two different mechanisms; tetL mediates active efflux of tetracycline from cells, the same mechanism commonly found in gram-negative bacilli (133), while tetM and tetN mediate resistance by a mechanism that protects the ribosomes from inhibition by tetracycline (25 (30) . The prevalence of strains highly resistant to various aminoglycosides varies from place to place but is generally highest for streptomycin (112, 144, 152) . Two mechanisms have been described which account for HLR of clinical isolates to streptomycin: ribosomal resistance and enzymatic modification by an adenylyltransferase (57, 112) . This enzyme appears to adenylylate the 6-hydroxyl position since it is not active against spectinomycin; unfortunately, even without HLR, spectinomycin is not a bactericidal agent and does not show synergism against enterococci (44, 112, 135). Eliopoulos et al. found streptomycin MICs of 4,000 to 16,000 pLg/ml (on dextrose phosphate agar) for strains with streptomycin adenylyltransferase, while MICs were up to 128,000 ,ug/ml for strains with ribosomal resistance (57) . HLR to kanamycin in strains without HLR to gentamicin is due to production of an aminoglycoside 3'-phosphotransferase (44, 112, 135) . This enzyme also has activity against amikacin. Although strains do not display HLR to amikacin, Krogstad (29, 112 (232) . HLR to gentamicin has also been reported in E. faecium and in community-acquired E. faecalis (58, 154) . As with HLR to streptomycin and kanamycin, HLR to gentamicin and other aminoglycosides eliminates synergism between penicillins and these aminoglycosides (46, 100, 135) . Various aminoglycoside-modifying enzyme activities have been found in these multiresistant strains, including streptomycin adenylyltransferase, 3'-phosphotransferase, 6'-AAC, and 2"-phosphotransferase (2"-APH) (44, 135, 152) . The last two enzyme activities were shown by Ferretti et al. to be due to a single fusion protein with two active regions, one that has 2"-APH activity and one that has 6'-AAC activity (77) . The combined activities result in HLR (as well as resistance to synergism) to gentamicin, sisomicin, netilmicin, tobramycin, kanamycin, and amikacin but not streptomycin (44, 135, 154) . Many of the strains studied have been able to transfer gentamicin resistance to other strains (100, 135, 152, 233) .
Beta-lactamase. Beta-lactamase-producing enterococci have now been reported from five cities: Houston, Tex.; Philadelphia, Pa.; Canonsville, Pa.; West Haven, Conn.; and Boston, Mass., where a cluster of strains was found at Boston Children's Hospital (104, 150, 163a, 164; Rhinehart et al., 28th ICAAC). I have recently been sent from Argentina three enterococci which produce beta-lactamase. In most instances, beta-lactamase has been encoded on a transferable plasmid that also encodes high-level gentamicin resistance; one of these plasmids has been shown to be a pheromone responsive plasmid (148) .
The resistance of beta-lactamase-producing strains is not detected by routine disk susceptibility testing (unlike nonbeta-lactamase-producing strains with high-level penicillin resistance, discussed below) because of an inoculum effect. When a low inoculum is used (like that used for disk testing), strains appear susceptible, but at a high inoculum (e.g., 107 CFU/ml) strains appear resistant (MIC, >500 ,ug/ml) (149) . An inoculum effect is also seen with beta-lactamase-producing staphylococci. It is due to the fact that low numbers of cells do not produce sufficient beta-lactamase to cause resistance. The enterococcal beta-lactamase hydrolyzes penicillin, ampicillin, and piperacillin (and other ureidopenicillins), which correlates with resistance to these compounds (149, 151) ; there is little or no inactivation of penicillinase-resistant semisynthetic penicillins, cephalosporins, or imipenem. The lack of efficacy of penicillin against beta-lactamase-producing strains has been confirmed in animal model studies (97, 104) . Hybridization studies have shown that the beta-lactamase gene is highly homologous to that from Staphylococcus aureus, although differences exist in the expression of these enzymes, namely, that the betalactamase from enterococci is constitutively produced and cell bound, whereas that from staphylococci is typically inducible and released into the extracellular medium (149, 151, 237 Penicillin resistance without beta-lactamase production. In a 1968 to 1969 survey of 382 enterococcal isolates, penicillin and ampicillin MICs were >100 jig/ml for one isolate and a penicillin MIC of 50 jug/ml was reported for one strain (209) ; occasional other papers have also reported MICs of penicillin in this range (13, 82, 224) . Other examples include the E. faecium in a recent neonatal nursery outbreak for which MICs of penicillin were >25 j1g/ml (46) and a strain of E. faecium reported recently by LeClercq et al. for which the penicillin MIC was 64 pig/ml (120) . Recent papers indicate that these highly penicillin-resistant strains are being recognized more often, perhaps because of heightened awareness of penicillin resistance or perhaps because they are becoming more common (28; F. L. Sapico, H. N. Canawati, V. J. Ginunas, and W. Tuddenham, Program Abstr. 28th ICAAC, abstr. no. 1074, 1988; J. M. Boyce, A. A. Medeiros, E. F. Papa, and G. Potter-Bynoe, Program Abstr. 28th ICAAC, abstr. no. 1075, 1988). The MICs of penicillin for these strains may be extreme examples of the "intrinsic resistance" common to E. faecium and associated with lowaffinity penicillin-binding proteins (224) or may represent acquired resistance.
Vancomycin resistance. The most recent resistance trait to emerge in enterococci is resistance to vancomycin; a number of papers and abstracts have been published since January 1988. Although MICs of vancomycin of -50 pig/ml have been noted for occasional enterococcal isolates, such strains apparently were very rare, and it is conceivable that certain of these may have been leuconostocs or other newly recognized, vancomycin-resistant, gram-positive organisms (209, 210) . Uttley et al. reported 55 strains of vancomycin-resistant enterococci from 22 patients with end-stage renal failure in England; 48 were E. faecium and 7 were E. faecalis (213) . Sources included blood, intraabdominal fluid, bile, and urine, among others. All were resistant to >64 pig of vancomycin per ml and MICs were >2,000 jig/ml for seven strains. Kaplan et al. reported a patient undergoing hemodialysis who had bacteremia and wound infection with a strain of E. gallinarum for which the MIC of vancomycin was 16 jig/ml (106) . Lutticken and Kunstmann reported E. faecium with a vancomycin MIC of 32 jig/ml (127) . Leclercq et al. reported vancomycin-resistant E. faecium from the feces of two patients with acute leukemia; the MICs were 512 and 1,024 pig/ml (120) . The resistance was shown to be plasmid mediated by novobiocin curing and transformation into S. sanguis. In recent publications, vancomycin resistance was reported to be inducible and to be transferable by conjugation or mobilization from E. faecalis and E. faecium to E. faecalis and/or E. faecium recipients (121, 158a, 192, 223b) . One strain could transfer vancomycin resistance to S. sanguis, Listeria monocytogenes, and E. faecalis but not to restriction-minus Staphylococcus aureus or Bacillus spp. (121, 192) . These represent the first examples among any organisms of transferable vancomycin resistance. It has now been shown that there are two types of resistance to vancomycin. One type, which mediates higher levels of resistance (MIC, .256 jig/ml), is associated with an inducible cytoplasmic membrane-associated protein of 39 kilodaltons (192) . The other type expresses lower levels of resistance and is associated with an inducible cytoplasmic membrane protein of 39.5 kilodaltons (223b). Although it is postulated that this protein may block vancomycin from its target site, DAla-D-Ala, the mechanism is not yet understood. One of the vancomycin resistance genes has been cloned, and a probe from this strain hybridizes only with enterococci with highlevel vancomycin resistance (MIC, -512 pug/ml) and not with strains for which MICs are 16 to 32 pug/ml, or with vancomycin-resistant leuconostocs or pediococci (R. Le Clercq, V. Coutant, S. Dutka-Malen, J. Duval, and P. Courvalin, Program Abstr. 29th ICAAC, abstr. no. 273, 1989).
MANAGEMENT OF ENTEROCOCCAL INFECTIONS Therapy
Urinary, soft-tissue, and miscellaneous infections. Enterococcal urinary and soft-tissue infections are typically treated with single-drug therapy, often ampicillin, penicillin, or vancomycin. Ureidopenicillins should also be adequate, although there is no reason to use these agents unless other bacteria are also suspected, such as in mixed abdominal infections. Ticarcillin is only moderately active in vitro against enterococci and has little role in therapy of enterococcal infections. Ciprofloxacin and norfloxacin have been used successfully for enterococcal UTIs, but the organism's susceptibility is marginal for treating systemic infections with this drug and breakthrough has occurred at other sites of enterococcal infections (231) . Nitrofurantoin may also be useful for UTIs. Data on the efficacy of other agents such as erythromycin, tetracycline, and chloramphenicol are limited, although erythromycin and chloramphenicol have transiently suppressed symptoms in endocarditis and meningitis, respectively, but are not curative (175, 178) . Rifampin is active in vitro but, like other agents, lacks bactericidal activity against enterococci alone or in combination with other agents and, in fact, can be antagonistic to betalactams; resistance develops rapidly in vitro when used alone (143) . For beta-lactamase-producing strains, imipenem, vancomycin, ampicillin-sulbactam, or amoxicillinclavulanic acid should adequately replace penicillin or ampicillin. Some vancomycin-resistant strains are also penicillin resistant, and their susceptibility to all possible agents should then be determined. Enterococcal meningitis is rare and has been treated with various regimens. Although intravenous ampicillin alone has occasionally resulted in cure (11) , a more reasonable approach would be to initiate therapy with intravenous ampicillin plus intravenous gentamicin (if the organism is not highly resistant) and to consider switching intravenous gentamicin to intraventricular gentamicin if the patient does not improve and CSF cultures remain positive. Rifampin has been used in enterococcal meningitis, but in one report of successful therapy it was given in conjunction with intraventricular vancomycin after the patient failed to respond to intravenous vancomycin plus gentamicin (178) .
Enterococcal bacteremia with a demonstrable extracardiac source generally responds well to the therapy that is directed to the primary site, such as ampicillin for 10 to 14 days. Although some authors may feel that penicillin alone is inappropriate for enterococcal bacteremia (129) (129) . The same authors also recommend 4 weeks of bactericidal therapy for patients for whom an extracardiac source cannot be identified, particularly when the enterococcus is present in pure culture and was community acquired (129) . Whether or not these lengthy regimens are truly necessary or whether shorter courses or single-drug therapy will suffice is not known.
Endocarditis. Therapy of enterococcal endocarditis has presented a dilemma since the 1940s, when it was noted that a number of patients were not cured by penicillin alone, in contrast to patients infected with "other" streptococci (13, 82, 125) . Although perhaps a third of patients have been cured with single-drug therapy, many patients failed such therapy, even when high doses of penicillin were used. This observation, together with the finding that better results were obtained with the use of penicillin plus streptomycin, established the idea that combined therapy is preferred (13, 82, 96, 111, 125, 131, 141, 175, 182, 185, 226) . In animal models of enterococcal endocarditis and by time-kill curves, combination therapy has also been shown to be superior to single-drug regimens such as penicillin, ampicillin, imipenem, and vancomycin (7, 35, 95, 184, 200, 204) .
For many years, streptomycin was the preferred aminoglycoside for use in enterococcal endocarditis; however, many strains are now highly resistant (MIC, >2,000 pug/ml) to streptomycin and thus are resistant to penicillin-streptomycin synergy (34, 90, 99, 226) . Many of these strains lack HLR to gentamicin and can still be treated with combination therapy. Whether or not gentamicin is the agent of choice for strains lacking HLR to streptomycin is somewhat controversial. Disadvantages of streptomycin are that it produces more irreversible ototoxicity and, in most hospitals, serum levels cannot be rapidly obtained. In general, low-dose regimens (such as 3 mg of gentamicin/kg per day) plus high-dose penicillin (20 x 106 U/day) or ampicillin (12 g/day) are preferred (132, 227) . The length of therapy is also debated; Wilson et al. (226) suggested that 4 weeks is adequate if patients have been ill for <3 months, although Scheld and Mandell still recommended 6 weeks for most patients (185) . For beta-lactamase-producing strains, ampicillin-sulbactam, vancomycin, or imipenem should be used in place of penicillin or ampicillin.
Currently, clinicians are faced with enterococci that are highly resistant to all aminoglycosides. When such strains cause endocarditis, adding an aminoglycoside adds nothing to the effect of the cell-wall-active agent alone but will expose patients to increased toxicity (29, 30, 97, 112, 135) . Optimal therapy for these patients is unknown. Based on historical accounts, some patients should be cured by singledrug therapy, but which agent should be used is not known. Some have suggested that ampicillin is inherently more bactericidal than penicillin (13) ; whether this is just the expected twofold or so higher activity (as is seen in the MICs) or whether the enterococcal killing by ampicillin exceeds this is not clear. Moreover, it is not known whether an MBC, or for that matter any in vitro or animal model criteria, can predict clinical cures. One group reported better success in a rat model of endocarditis by using continuousinfusion ampicillin versus intermittent ampicillin for a strain of enterococcus highly resistant to gentamicin (205) . However, that strain also showed a 103-CFU/ml decrease from a 107-CFU/ml inoculum in time-kill curves, using 5, 10, and 250 ,ug of ampicillin per ml, and the authors comment that other strains may display more tolerance to ampicillin. Another study showed efficacy of ampicillin alone in animals with endocarditis treated for 21 days via a subcutaneous chamber (208) ; a single strain was studied. Since some patients and animals with enterococcal endocarditis are also cured by penicillin alone, these results are not surprising.
Again, however, care must be taken with generalizations, since failures of ampicillin to cure endocarditis in patients infected with a strain of E. faecalis resistant to multiple aminoglycosides have been reported (76, 108) . It should also be reiterated that, in the absence of HLR, ampicillin plus an aminoglycoside is superior to ampicillin alone (73, 202) .
Other agents also show little promise for reliable, successful, single-drug therapy. Vancomycin alone has been reported to cure some patients with enterococcal endocarditis. In one study, however, the biochemical tests used were insufficient to separate enterococci from some streptococci. To cast further doubt on the bacteriologic identification, all of the enterococci were said to be susceptible to cephalothin and one to clindamycin, unusual properties for enterococci (79) . In vitro, vancomycin is usually not bactericidal, and it does no better in animal models than penicillin alone (27, 99, 104, 135, 205, 217) . Among other agents that have been evaluated, ciprofloxacin was less effective than procaine penicillin in controlling enterococcal endocarditis (75, 104, 195) . Mezlocillin looked better than ampicillin in one study, but higher doses were used (73) . Imipenem also gave no better results than other beta-lactams alone (7, 184) . Teicoplanin was found to be equivalent to ampicillin in rabbits with enterococcal endocarditis, and the single agents were less active than when combined with gentamicin for strains lacking HLR (202) . Rifampin is indifferent or antagonistic to beta-lactams (143) . Daptomycin (LY146032), an agent with better in vitro bactericidal activity than beta-lactams and vancomycin, has not had good success in early in vivo trials; this may be related to the lower effect of daptomycin that is observed in 50% human serum in vitro (173) . When fosfomycin is combined with daptomycin, there is increased bactericidal activity against enterococci even at low concentrations of daptomycin; this bactericidal activity is not reversed by 50% serum (173) .
In summary, although based on little firm data, high-dose ampicillin, perhaps by continuous infusion for a prolonged period of time, seems a reasonable choice for patients with endocarditis whose infecting strain is susceptible to ampicillin but highly resistant to all aminoglycosides. All (38, 138, 145, 223 ).
An apparently rare example of lack of synergism without HLR was a strain of E. faecalis that showed selective resistance to a combination of penicillin plus gentamicin (140) . This strain was isolated from the blood of a patient with enterococcal endocarditis who relapsed despite repeated courses of penicillin plus gentamicin. Several isolates from this patient were studied and found to be resistant to the combination of penicillin (ampicillin) plus gentamicin but susceptible to the synergistic combination of penicillintobramycin. The strain did not show HLR to gentamicin (MIC of gentamicin, 8 pug/ml). No aminoglycoside-modifying enzymes were found, but the uptake of radiolabeled gentamicin was not enhanced by the addition of penicillin whereas the uptake of radiolabeled tobramycin was enhanced. The patient was subsequently cured by the combination of ampicillin-plus-tobramycin therapy (140) .
Another possible, but not proven, exception might be enterococci that are resistant to streptomycin on the basis of production of streptomycin adenylyltransferase; for such strains, MICs of streptomycin are as low as 4,000 ,ug/ml (57) . (144) .
Other workers have used various media and various inocula.
We streaked a heavy unquantitated inoculum onto brain heart infusion agar with 1,000 tig of gentamicin per ml and .15 MHA 180 6 .17 MHA 198 Disks were 6 mm in diameter. b HLR was defined as a MIC of >2,000 ,ug/ml, as resistance to synergism, as resistant by one of several other techniques, or a combination of these (177, 180, 198 120 pug of gentamicin and tobramycin and 300 Lg of streptomycin were evaluated on Mueller-Hinton and Trypticase soy agars, both with 5% sheep blood, and the results were compared with MIC determinations on Mueller-Hinton agar. Only 3 of 70 strains had HLR to gentamicin and 14 had HLR to streptomycin; these strains had no zone of inhibition around the high-content disks. All "susceptible" strains (i.e., those lacking HLR) had zones of .12 mm for streptomycin and .16 for gentamicin; MICs of these agents were <125 ,ug/ml.
With tobramycin, strains with MICs of 4,000 VLg/ml had no zone of inhibition around the 120-,ug tobramycin disk and a strain with a MIC of 2,000 pg/ml had a zone of 8 mm. These authors suggest that, when susceptibility powder is not available, vials of clinical material can be used (177) , as has been done in other studies (135, 144, 200) .
Sahm and Torres evaluated disks with both 300 and 2,000
,ug of streptomycin and 120 and 2,000 ,ug of other aminoglycosides, using Mueller-Hinton agar as well as MuellerHinton agar with 5% sheep blood ( (234) . Of 5,797 isolates screened, 508 grew in the single well; gentamicin MICs for 505 were >2,000 ,ug/ml, and for the other 3, they were 500 to 1,000 ,ug/ml. Unfortunately, synergy study results were not provided for these three strains. Sahm and Torres evaluated 63 E. faecalis strains in a 1-ml volume test with dextrose phosphate broth and Mueller-Hinton broth and an inoculum of 105 CFU/ml. Both broths gave good results with streptomycin, gentamicin, and kanamycin, although a few resistant strains were missed, indicating that an aminoglycoside would have been used needlessly; results were fair to poor for tobramycin (181) .
Spiegel compared results with the following: (i) an inhouse microdilution method with 500 ,ug of gentamicin per ml, 2,000 ,ug of streptomycin per ml, Mueller-Hinton broth, and an inoculum of 7.5 x 105 CFU/ml; (ii) the MicroScan microdilution (POS MIC2) panels (MicroScan, W. Sacramento, Calif.), using the same concentrations as above and an inoculum of 105 CFU/ml; (iii) an in-house tube macrodilution method (using Mueller-Hinton broth, the same concentrations, and an inoculum of 7.5 x 105 CFU/ml); and (iv) the high-content disks discussed above (198 (177, 180, 198) ( Table 2 ). For streptomycin, disks containing 300 jig generated zones of 6 to 10 mm for strains with HLR, and for nonresistant strains, zones have been .12 mm (177, 180, 198) . In the only study reporting strains with a zone of up to 10 mm, all nonresistant strains had zones of .16 mm (198) .
(ii) In-house broth microdilution systems also appear highly reliable, although a few strains have been missed with streptomycin, 2,000 jig/ml (198, 234) . This might result in the use of streptomycin when it was not indicated but is perhaps a less severe error, unless marked toxicity occurred, than failing to use an aminoglycoside when it would result in synergism.
(iii) At the current time, some caution should be used with prepackaged or automated systems that have not been fully evaluated with published data comparing the system with standard methods, such as a full-range MIC determination or the agar plate method. The verification of these systems is particularly important because so many clinical laboratories now depend on prepackaged automated systems for determination of susceptibility. As suggested by one author, "a multicenter study performed under the guidance of the NCCLS [National Committee for Clinical Laboratory Standards] may be appropriate" (198) .
(iv) There is usually little need to test aminoglycosides other than streptomycin or gentamicin since these are the agents for which there are the most clinical data. To date, all strains with HLR to gentamicin have also had resistance to synergism and/or HLR to tobramycin, sisomicin, netilmicin, kanamycin, and amikacin by virtue of the 2"-APH-6'-AAC. This enzyme is not active against streptomycin so that gentamicin-resistant strains are not necessarily resistant to streptomycin; in other words, a variable percentage of strains will have HLR to gentamicin while lacking HLR to streptomycin (100, 135, 152, 154) . If one considers using amikacin in combination with a cell-wall-active agent, it will be necessary to test for HLR to kanamycin and gentamicin since each causes resistance to synergism with amikacin. If one considers using tobramycin, then screening for HLR to gentamicin and species identification are needed since E. faecium are resistant to penicillin-plus-tobramycin synergism (138, 145, 223) .
CONCLUSION
The recent attention focused on the enterococcus is likely to continue in the foreseeable future. The ability of enterococci to colonize the gastrointestinal tract, plus the many intrinsic and acquired resistance traits, means that these organisms, which usually seem to have relatively low intrinsic virulence, are given an excellent opportunity to become VOL. 3, 1990 on January 18, 2018 by guest http://cmr.asm.org/ Downloaded from secondary invaders. Since nosocomial isolates of enterococci have displayed resistance to essentially every useful antimicrobial agent, it will likely become increasingly difficult to successfully treat and control enterococcal infections. This will be particularly true when the various resistance genes came together in a single strain, an event almost certain to occur at some time in the future.
